Article
Oncology
Hong Yang, Sha Li, Wan Li, Yihui Yang, Yizhi Zhang, Sen Zhang, Yue Hao, Wanxin Cao, Fang Xu, Hongquan Wang, Guanhua Du, Jinhua Wang
Summary: ActD has a synergetic effect on TNBC with Dox via P53-dependent apoptosis and may be a new choice for the treatment of TNBC.
Review
Medicine, Research & Experimental
Charlie Marvalim, Arpita Datta, Soo Chin Lee
Summary: The transcription factor p53 plays a crucial role in regulating cellular processes and is activated in response to genotoxic stress. In breast cancer, p53's tumor suppressive activities are often compromised by the overexpression of MDM2 or mutation, with the latter being more common in hormone receptor-negative patients. Targeting both wild-type and mutant p53 in different subtypes of breast cancer has potential clinical relevance, and various therapeutic strategies including small molecule inhibitors, peptides, PROTACs, and genetic-based approaches are being developed. This review highlights the ongoing efforts to overcome p53 inactivation in breast tumors and discusses the efficacy and limitations of these therapeutic strategies.
Review
Oncology
Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
Summary: TNBC, characterized by absence of ER, PR, and HER2 expression, is a highly aggressive subtype of breast cancer. Conventional chemotherapy remains the main treatment, but the lack of targeted therapies has led to exploration of PARP inhibitors and immune checkpoint inhibitors as potential options. Other agents targeting various pathways are also under investigation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Materials Science, Multidisciplinary
Qingxin Mu, Guanyou Lin, Mike Jeon, Hui Wang, Fei-Chien Chang, Richard A. Revia, John Yu, Miqin Zhang
Summary: This study presents a multifunctional nanoparticle formulation targeting TNBC cells and dendritic cells, inducing tumor apoptosis through multiple mechanisms and significantly inhibiting tumor growth and metastasis while extending survival in a drug-resistant mouse model of TNBC. The promising platform may substantially improve therapeutic efficacy for treating metastatic TNBC.
Article
Oncology
Yingnan Si, Ya Zhang, Hanh Giai Ngo, Jia-Shiung Guan, Kai Chen, Qing Wang, Ajeet Pal Singh, Yuanxin Xu, Lufang Zhou, Eddy S. Yang, Xiaoguang (Margaret) Liu
Summary: This study focused on developing a new formulation of combined chemotherapies facilitated with a targeted delivery vehicle for treating TNBC. In vivo evaluations confirmed the anti-tumor efficacy of the treatment, and the targeted liposomes effectively delivered therapeutic drugs to TNBC tumors, reducing side effects. The study demonstrated the potential of the targeted liposomal drug formulation for future clinical trials in TNBC treatment.
Article
Oncology
Zahi Mitri, Nour Abuhadra, Shaun M. Goodyear, Evthokia A. Hobbs, Andy Kaempf, Alastair M. Thompson, Stacy L. Moulder
Summary: By applying an Evolutionary Action Score (EAp53) to functionally characterize TP53 mutations in TNBC patients, this study found that EAp53 stratification may identify TP53 mutations associated with worse outcomes, indicating potential for enhanced clinical management.
NPJ PRECISION ONCOLOGY
(2022)
Review
Oncology
Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu
Summary: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, lacks expression of estrogen receptor, progesterone receptor, and HER2. Although chemotherapy is the main treatment for TNBC, its effectiveness is limited. Various targeted therapies, including inhibitors of the PI3K/AKT/mTOR pathway, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody-drug conjugates, have emerged. Additionally, immune checkpoint inhibitors such as pembrolizumab, atezolizumab, and durvalumab, are being extensively investigated. This review summarizes recent advances in targeted therapy and immunotherapy in TNBC, aiming to serve as a reference for future development of personalized treatment for TNBC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Selase Ativui, Cynthia A. Danquah, Paul Poku Sampene Ossei, Michael Ofori
Summary: This study demonstrated that palmatine has the potential to improve hypoxemia, ameliorate metastasis-associated lung injury, decrease lung MTA1 expression, and increase p53 expression in the treatment of lung metastasis from triple negative breast cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Natacha Jugniot, Tarik F. Massoud, Jeremy J. Dahl, Ramasamy Paulmurugan
Summary: TNBC is a highly heterogeneous breast cancer subtype with poor prognosis. In this study, we developed a targeted diagnostic agent using nanobubbles based on the TNBC cancer cell membrane. This agent showed increased extravasation and retention in a TNBC mouse model, and immunofluorescence analysis confirmed its presence in the tumor microenvironment. This approach has the potential to improve diagnosis and targeted drug delivery for TNBC, regardless of tumor tissue heterogeneity.
JOURNAL OF NANOBIOTECHNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yingnan Si, Kai Chen, Hanh Giai Ngo, Jia Shiung Guan, Angela Totoro, Zhuoxin Zhou, Seulhee Kim, Taehyun Kim, Lufang Zhou, Xiaoguang Liu
Summary: This study developed and evaluated a natural compound, verrucarin A (Ver-A), delivered by targeted extracellular vesicles (EV), for the treatment of triple-negative breast cancers (TNBCs). The results showed that the targeted mAb-EV-Ver-A could effectively target TNBC and deliver the drug with minimal side effects.
Article
Oncology
Ghazal Nabil, Rami Alzhrani, Hashem O. Alsaab, Mohammed Atef, Samaresh Sau, Arun K. Iyer, Hossny El Banna
Summary: Triple-negative breast cancer (TNBC) is a challenging and aggressive tumor with limited therapeutic options. Combination therapies, such as using apoptosis inducers and JAK/STAT3 inhibitors, have shown improvement in TNBC cell killing activity. CD44 targeted polymeric nanoparticles and Hyaluronic acid-tagged nanoparticles have enhanced drug activity and tumor accumulation, leading to improved therapeutic efficacy for TNBC treatment.
Article
Engineering, Biomedical
Zhenghu Chen, Zihua Zeng, Quanyuan Wan, Xiaohui Liu, Jianjun Qi, Youli Zu
Summary: This study demonstrates a novel immunotherapeutic approach for targeting triple-negative breast cancer (TNBC) using aptamer-engineered NK cells. The synthetic aptamer probes selectively target TNBC cell lines and trigger apoptosis and death of cultured TNBC cells. Systemic administration of aptamer-engineered NK cells inhibits lung metastasis in mice harboring TNBC xenografts.
Article
Biochemistry & Molecular Biology
Elizabeth A. Bowling, Jarey H. Wang, Fade Gong, William Wu, Nicholas J. Neill, Ik Sun Kim, Siddhartha Tyagi, Mayra Orellana, Sarah J. Kurley, Rocio Dominguez-Vidana, Hsiang-Ching Chung, Tiffany Y-T Hsu, Julien Dubrulle, Alexander B. Saltzman, Heyuan Li, Jitendra K. Meena, Gino M. Canlas, Srinivas Chamakuri, Swarnima Singh, Lukas M. Simon, Calla M. Olson, Lacey E. Dobrolecki, Michael T. Lewis, Bing Zhang, Ido Golding, Jeffrey M. Rosen, Damian W. Young, Anna Malovannaya, Fabio Stossi, George Miles, Matthew J. Ellis, Lihua Yu, Silvia Buonamici, Charles Y. Lin, Kristen L. Karlin, Xiang H-F Zhang, Thomas F. Westbrook
Summary: This study reveals that mis-spliced RNA can trigger tumor cell death through viral mimicry, where dsRNA-binding proteins recognize mis-spliced RNA and induce antiviral signaling and apoptosis. Additionally, the findings suggest that STTs may activate anti-tumor immune pathways by responding to global aberrations of RNA splicing in cancer.
Article
Medicine, Research & Experimental
Gu Xiao, George K. Annor, Kimberly Fung, Outi Keinanen, Brian M. Zeglis, Jill Bargonetti
Summary: The novel nucleus-penetrating mtp53 peptide Cy5p53Tet shows high cellular uptake in TNBC, particularly in cells expressing mtp53. This peptide has the potential for clinical application as a near-infrared fluorescence imaging agent, providing a possibility for fluorescence-guided surgery.
MOLECULAR PHARMACEUTICS
(2021)
Article
Engineering, Biomedical
Lu Lu, Genhua Liu, Chuanchuan Lin, Ke Li, Tingting He, Jixi Zhang, Zhong Luo, Kaiyong Cai
Summary: The study introduces a novel nanocarrier for breast cancer treatment that targets both tumors and mitochondria, demonstrating great potential in enhancing the efficacy of cancer therapy.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Chemistry, Multidisciplinary
Rong-Hui Wang, Ya-Ling Li, Hong-Jiao He, You-Cai Xiao, Fen-Er Chen
Summary: The catalytic enantioselective diorganozinc additions to cyclic diketones, including pyrazolin-4,5-diones and isatins, have been developed to produce chiral cyclic tertiary alcohols with good to excellent yields (up to 97%) and enantioselectivities (up to 95% ee) in the presence of morpholine-containing chiral amino alcohol ligand. This protocol is notable for its mild reaction conditions, lack of Lewis acid additives, and broad functional group tolerance.
CHEMISTRY-A EUROPEAN JOURNAL
(2021)
Review
Chemistry, Organic
Hui-Jing Wang, Yang-Yang Zhong, You-Cai Xiao, Fen-Er Chen
Summary: This review summarizes the historical perspective and recent advances in the stereoselective synthesis of beta-nucleosides and their analogues, and introduces three synthetic strategies.
ORGANIC CHEMISTRY FRONTIERS
(2022)
Article
Biology
Ramkrishna Mitra, Clare M. Adams, Christine M. Eischen
Summary: CRISPR screens at the genome scale have identified co-essential pathways and critical functions of lncRNAs. Furthermore, this study predicts the importance of poorly characterized lncRNAs in cancer and their role in proliferation and growth. The findings provide valuable insights into lncRNA-mediated regulation of cellular fitness in cancer and address current limitations in lncRNA research.
Review
Biology
Brian C. Grieb, Christine M. Eischen
Summary: Cancer is the second leading cause of death globally. MYC plays a critical role in cancer cell growth, but drugs targeting MYC are difficult to obtain. A protein called MTBP has been found to be associated with MYC and helps its pro-growth and cancer-promoting function. Elevated levels of MTBP in cancer are associated with reduced patient survival. Decreasing MTBP levels can inhibit cancer cell growth and induce cancer cell death, suggesting that MTBP may represent a new cancer drug target.
Article
Chemistry, Organic
Hong-Jiao He, Rui-Qi Wang, Lin-Xi Wan, Li-Yan Zhou, Hong-Yan Li, Guo-Bo Li, You-Cai Xiao, Fen -Er Chen
Summary: This study demonstrates the organocatalytic asymmetric Morita-Baylis-Hillman (MBH) reaction of isatin derivatives with various vinyl sulfones. Chiral sulfone-containing 3-hydroxyoxindoles were obtained with good to high yields and enantioselectivities. It provides an innovative approach to incorporate the sulfone functional group for the synthesis of chiral 3-hydroxyoxindoles in asymmetric MBH reactions using activated alkenes with sulfone moiety.
JOURNAL OF ORGANIC CHEMISTRY
(2023)
Article
Chemistry, Multidisciplinary
Xu Zhou, Ramkrishna Mitra, Fei Hou, Shunheng Zhou, Lihong Wang, Wei Jiang
Summary: Adenosine-to-inosine RNA editing plays a critical role in cancer therapy response. A comprehensive identification of drug resistance-related RNA editing events and understanding of their mechanism is lacking. This study identifies 7157 differential editing sites (DESs) from 98,127 informative RNA editing sites in tumor tissues and reveals various editing patterns in resistant samples. RNA-binding proteins are found to potentially regulate these editing events. DESs are significantly enriched in 3'-UTRs and their impact on miRNA regulations is explored. Genes associated with DESs are involved in drug resistance-related functions. A convenient online resource for retrieving DESs is built. These findings provide insights into the landscape and regulatory mechanism of RNA editing in drug resistance and offer new therapeutic targets for reversing drug resistance.
Review
Pharmacology & Pharmacy
You-Cai Xiao, Fen-Er Chen
Summary: Vinyl sulfones play important roles in drug discovery as structural motifs and versatile building blocks. They target various macromolecular targets and have been applied in the design of anticancer, anti-infective, anti-inflammatory, and neuroprotective agents. However, further improvement is needed in terms of drug-like properties and the chemical space of vinyl sulfones.
EXPERT OPINION ON DRUG DISCOVERY
(2023)
Article
Chemistry, Organic
Zhao-Feng Li, Hong-Jiao He, Rong-Hui Wang, Li-Yan Zhou, You-Cai Xiao, Fen-Er Chen
Summary: This study reports the asymmetric copper-catalyzed alkynylation reactions of pyrazole 4,5-diones in the presence of a hydroxyl oxazoline ligand derived from low cost and easily accessible chloramphenicol base (ANP). The notable features of this protocol include mild and base additive free reaction conditions, and broad functional group tolerance.
ORGANIC CHEMISTRY FRONTIERS
(2022)
